Jefferies initiates Oxford Biomedica stock with Buy rating, citing undervaluation

Jefferies initiated coverage on Oxford Biomedica (OTC:OXBDF) with a Buy rating and a GBP5.66 price target, identifying the company as a high-quality Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) that appears undervalued. Despite a strong track record, Oxford Biomedica's shares have weakened year-to-date, with current pricing reflecting growth expectations below market and guidance for 2025-2030. Jefferies believes this presents significant upside potential if the company achieves its targets.

Analysis

Jefferies has initiated coverage on Oxford Biomedica (OTC:OXBDF) with a 'Buy' rating and a price target of GBP 5.66, signaling a bullish outlook. The firm positions Oxford Biomedica as a high-quality Cell and Gene Therapy (CGT) Contract Development and Manufacturing Organization (CDMO) whose shares are currently undervalued. This valuation disconnect is attributed to broad sector uncertainties rather than company-specific issues, as Jefferies highlights the company's strong track record, commercial experience, and positive customer metrics. Despite these strengths, the stock has underperformed year-to-date. The core of the investment thesis is that the current market price implies growth expectations for the 2025-2030 period that are below both company guidance and market consensus, creating a significant upside potential contingent on the company meeting its stated financial targets.

Key Decisions for Investors

• Investors with a bullish view on the Cell and Gene Therapy sector may consider the stock, as Jefferies identifies it as an undervalued, high-quality operator with significant upside potential.
• The investment thesis is heavily dependent on the company achieving its 2025-2030 targets; therefore, it is crucial to monitor corporate earnings and guidance updates for any signs of deviation from the projected growth trajectory.
• Given that the stock's weakness is linked to sector-wide sentiment, investors should evaluate if the current entry point adequately compensates for the inherent risks within the CGT space.